Simon Fry Joins Conduit Pharmaceuticals Board Of Directors

Conduit Pharmaceuticals Inc., a clinical-stage, multi-asset life sciences company, has announced the appointment of Simon Fry to its Board of Directors. Mr. Fry brings over three decades of experience in investment banking, having held senior executive roles at leading financial institutions.  

In 2003, he became CEO of Crosby Asset Management, following a distinguished career at Nomura, where he served as Managing Director, European Board member, and a key participant in both the risk and credit committees. At Nomura, Mr. Fry established the Asset Investment Group, focusing on identifying undervalued credit and equity opportunities, and led the development of the International Markets Division, overseeing European equity, fixed income, and derivatives operations, including primary market origination.  

Before Nomura, Mr. Fry spent 14 years at Credit Suisse First Boston (CSFB), trading various securities and founding the Asset Trading Group as Managing Director. Under his leadership, the team delivered substantial returns over several years. Based in Los Angeles, Mr. Fry will officially join Conduit's Board after the company’s annual meeting on December 18, 2024. He will also serve on the Audit and Compensation Committees, leveraging his deep expertise in capital markets and strategic asset management to support Conduit's growth plans.

Dr. David Tapolczay, Chief Executive Officer of Conduit Pharmaceuticals, said in a statement, "Simon's depth of experience in capital markets and investment strategy brings tremendous value to Conduit as we expand our pipeline and explore new opportunities for growth. We welcome Simon to the Board and look forward to leveraging his expertise to enhance our strategic initiatives and maximise shareholder value."